B95
Conditions
Interventions
Group 1: Subgroup A:
- Estimated glomerular filtration rate (eGFR) 36
Group 2: Subgroup B:
- estimated glomerular filtration rate (eGFR) >=90 mL/min/1.73 m²
- Simplified Acute Physiology Score (SAPS)
Sponsors
Lehrstuhl für Hygiene und Umweltmedizin, Department für Humanmedizin, Fakultät für Gesundheit
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients >/= 18 years of age admitted to the surgical intensive care unit (OITS) of the hospitals of the city of Cologne, who received vancomycin as continuous infusion and for whom at least one vancomycin serum level was available
Exclusion criteria
Exclusion criteria: Patients < 18 years; internal medicine patients; intermittent vancomycin therapy; change of vancomycin infusion modality (intermittent/continuous); therapy duration < 2 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Failure: all cause mortality in the ICU, all cause in-hospital mortality, in-hospital mortality at day 30 after initiation of continuous infusion of vancomycin Toxicity: nephrotoxicity, defined as new onset of acute kidney injury (AKI) according to Acute Kidney Injury Network (AKIN) or KDIGO, between the start of treatment until three days after the end of continuous infusion of vancomycin | — |
Secondary
| Measure | Time frame |
|---|---|
| Failure: clinical and microbiological treatment failure Toxicity: time to onset of AKI, frequency of different AKI stages, reversibility of AKI at hospital discharge, change in renal function between the start of continuous infusion of vancomycin and day 28. | — |
Countries
Germany
Contacts
Public ContactFrauke Mattner
Lehrstuhl für Hygiene und Umweltmedizin, Department für Humanmedizin, Fakultät
Outcome results
None listed